TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03253107

Intervention type: DRUG
Intervention: Chemotherapy
Description: Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin

Intervention type: DRUG
Intervention: Chemotherapy
Description: Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin

Intervention type: DRUG
Intervention: Chemotherapy
Description: Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin

Intervention type: DRUG
Intervention: Chemotherapy
Description: Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin
Study: NCT01502423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
Study: NCT01662908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban tosylate
Description: edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
Study: NCT05654285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cola beverage with sucrose and stevia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cola beverage with sucrose and stevia
Study: NCT03049332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self- and family-management intervention sessions
Description: The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
Study: NCT04803045

Intervention type: OTHER
Intervention: Follow up email
Description: Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
Study: NCT01662908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin/unfractionated heparin
Description: enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
Study: NCT04792333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: firibastat
Description: Single oral dose of 500 mg administration on Day 1
Study: NCT00038207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Vincristine
Description: Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
Study: NCT01829750

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac progenitor cell infusion
Description: (Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1.

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Cardiac progenitor cell infusion
Description: (Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1.
Study: NCT01947439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
Study: NCT03727802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-250
Description: single and multiple doses (4 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single and multiple doses (4 weeks)
Study: NCT02260791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKB327
Description: Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
Study: NCT01404325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: centre specific CNI-based triple drug immunosuppression
Study: NCT02260791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
Study: NCT04025749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Executive Functions training
Description: Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Care as usual
Study: NCT00198042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of the ACL
Description: Surgical reconstruction of the ACL
Study: NCT01404325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
Study: NCT00480272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab, plus prednisone
Description: adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab plus placebo
Description: adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
Study: NCT00653146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
Study: NCT02865785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
Study: NCT00351026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: short-term methadone maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: short-term methadone maintenance
Study: NCT03042767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-124E
Description: IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
Study: NCT00554229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10 mg oral tablet once daily
Study: NCT03042767

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study: NCT01319058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy
Description: Each arm will be treated by one of the three methods in addition to adenoidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy
Description: Each arm will be treated by one of the three methods in addition to adenoidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy
Description: Each arm will be treated by one of the three methods in addition to adenoidectomy
Study: NCT02602548

Intervention type: OTHER
Intervention: Culture
Description: Specimens will be obtained and sent to the lab for cultures.
Study: NCT00554229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet once daily
Study: NCT02961049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival displacement
Description: Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
Study: NCT00653146

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyles
Description: In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
Study: NCT05323942

Intervention type: OTHER
Group type: OTHER
Intervention: Education and Exercise Therapy Group
Description: 82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise.
Study: NCT02137733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Study: NCT00704626

Intervention type: OTHER
Intervention: Blood Draw
Description: A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.

Intervention type: OTHER
Intervention: Cheek swab
Description: A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
Study: NCT00785148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
Study: NCT01916174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Subject will receive a single injection (s.c.) of IDegLira B5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Subject will receive a single injection (s.c.) of IDegLira V2
Study: NCT04283422

Intervention type: DIAGNOSTIC_TEST
Intervention: Biofire filmarray
Description: Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray

Intervention type: DIAGNOSTIC_TEST
Intervention: Biofire filmarray
Description: Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray
Study: NCT04252339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-1971
Description: RLY-1971 is an oral inhibitor of SHP2.
Study: NCT01557517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Oral Rinse
Description: Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral rinse
Description: Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
Study: NCT01471730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Normal saline will be administered to control patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prothrombin complex
Description: After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
Study: NCT02175901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: antisecretory drug of each quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: antisecretory drug of each quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: one component of each quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: one component of each quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: antibiotic of each quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic of each quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic of the amoxicillin/metronidazole-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
Study: NCT01720888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: Intracoronary implantation of bone marrow-derived mesencymal stem cells
Study: NCT02737904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APT
Description: APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Personalised in-patient rehabilitation programme

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Personalised in-patient rehabilitation programme
Study: NCT03123068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CocoaVia®
Description: CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
Study: NCT04370834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study: NCT01669603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bl-04
Description: The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: rhinovirus for experimental challenge

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rhinovirus
Description: rhinovirus for experimental challenge
Study: NCT04359797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone
Description: Provider-recommended guidance on prone positioning of patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No provider-recommendation, patients will remain in their natural choice of position
Study: NCT04410614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free epithelial (gingival) graft
Description: 1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
Study: NCT02843984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Study: NCT01918202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg PF-02545920
Description: Subject will receive a single dose of 20 mg PF-02545920.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
Study: NCT04371107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consultation
Description: Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consultation
Description: Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
Study: NCT01873378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg
Study: NCT04876105

Intervention type: OTHER
Intervention: Assesment of treatment preference
Description: Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants

Intervention type: OTHER
Intervention: Assesment of treatment preference
Description: Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
Study: NCT01495702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNRTI
Description: NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) administered according to prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild
Description: Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
Study: NCT00616421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: 1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: 2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed meningococcal ACWY vaccine
Description: 1 injection of the licensed meningococcal ACWY was administered intramuscularly
Study: NCT00958893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: one 25 mg capsules
Study: NCT00348829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve repair
Description: surgical mitral valve repair
Study: NCT00852007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
Description: 1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
Study: NCT01912261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule orally daily times 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide iron complex
Description: 150 mg daily orally times 84 days